Advertisement

Neurologic Manifestations of Systemic Rheumatologic Diseases

  • Michael J. Bradshaw
  • Shamik Bhattacharyya
  • Nagagopal Venna
  • Jonathan F. Cahill
Chapter
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

As the field of autoimmune neurology develops, the role of the neurologist in the management of patients with systemic autoimmune disease is increasing. This chapter briefly reviews the neurologic manifestations, diagnostic approach, and treatment of neurosarcoidosis, IgG-4-related disease, Behçet syndrome, Sjögren syndrome, lupus, and rheumatoid arthritis. The neurologic manifestations of these conditions include parenchymal brain and brainstem disease, myelopathy, radiculopathy, myopathy, and all forms of peripheral neuropathy. Recognizing when a neurologic concern is related to immune-mediated or alternative mechanisms is a critical role for the neurologist as treatment decisions may be based on this assessment. Familiarity with the neurologic manifestations of systemic rheumatologic disease is therefore critical. The approach to treatment depends on the underlying mechanisms of disease and decisions should be made in consultation with other experts assisting in the clinical care of an individual patient.

Keywords

Neurosarcoidosis Behçet Sjögren syndrome Rheumatoid arthritis Systemic lupus erythematosus Autoimmune neurology Neuro-rheumatology Neurologic complications Rheumatology IgG-4-related disease 

References

  1. 1.
    Lopez-Chiriboga AS, Clardy SL. Emerging subspecialties in neurology: autoimmune neurology. Neurology. 2017;89(11):e129–e33.PubMedCrossRefGoogle Scholar
  2. 2.
    Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Rossi G, Cavazza A, Colby TV. Pathology of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):36–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215–28.CrossRefGoogle Scholar
  5. 5.
    Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc. 2016;91(2):183–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.PubMedCrossRefGoogle Scholar
  7. 7.
    Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–6.PubMedGoogle Scholar
  8. 8.
    Krumholz A, Stern BJ. Neurologic manifestations of sarcoidosis. Handb Clin Neurol. 2014;119:305–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand. 1986;73(3):283–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol. 2007;64(5):691–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Ferriby D, de Seze J, Stojkovic T, Hachulla E, Wallaert B, Destee A, et al. Long-term follow-up of neurosarcoidosis. Neurology. 2001;57(5):927–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Carlson ML, White JR Jr, Espahbodi M, Haynes DS, Driscoll CL, Aksamit AJ, et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients. Otol Neurotol. 2015;36(1):156–66.PubMedGoogle Scholar
  14. 14.
    Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017;89(20):2092–100.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Ungprasert P, Matteson EL. Neurosarcoidosis. Rheum Dis Clin N Am. 2017;43(4):593–606.CrossRefGoogle Scholar
  16. 16.
    Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449–60.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Bagnato F, Stern BJ. Neurosarcoidosis: diagnosis, therapy and biomarkers. Expert Rev Neurother. 2015;15(5):533–48.PubMedCrossRefGoogle Scholar
  19. 19.
    Bathla G, Watal P, Gupta S, Nagpal P, Mohan S, Moritani T. Cerebrovascular manifestations of neurosarcoidosis: an underrecognized aspect of the imaging spectrum. AJNR Am J Neuroradiol. 2018;39(7):1194–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology. 1987;37(3):461–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci. 2011;1:15.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Lury KM, Smith JK, Matheus MG, Castillo M. Neurosarcoidosis—review of imaging findings. Semin Roentgenol. 2004;39(4):495–504.PubMedCrossRefGoogle Scholar
  23. 23.
    Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Investig. 2002;25(7):650–62.CrossRefGoogle Scholar
  24. 24.
    Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001;248(5):363–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, Ryerson LZ, Kister I. Multiple sclerosis and sarcoidosis: A case for coexistence. Neurol Clin Pract. 2019;9(3):218–27. PMID:31341709.Google Scholar
  26. 26.
    Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16(1):2–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Spiegel DR, Morris K, Rayamajhi U. Neurosarcoidosis and the complexity in its differential diagnoses: a review. Innov Clin Neurosci. 2012;9(4):10–6.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3(7):397–407.PubMedCrossRefGoogle Scholar
  29. 29.
    Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret S, Dormont D, et al. Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol. 2017;74(11):1336–44.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Junger SS, Stern BJ, Levine SR, Sipos E, Marti-Masso JF. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology. 1993;43(2):333–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chapelon-Abric C, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore). 2010;89(2):133–40.CrossRefGoogle Scholar
  32. 32.
    Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182(2):289–95.PubMedCrossRefGoogle Scholar
  33. 33.
    Hashmi M, Kyritsis AP. Diagnosis and treatment of intramedullary spinal cord sarcoidosis. J Neurol. 1998;245(3):178–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Zalewski NL, Krecke KN, Weinshenker BG, Aksamit AJ, Conway BL, McKeon A, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87(7):743–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016;79(3):437–47.PubMedCrossRefGoogle Scholar
  36. 36.
    Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology. 1991;41(10):1558–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Heij L, Dahan A, Hoitsma E. Sarcoidosis and pain caused by small-fiber neuropathy. Pain Res Treat. 2012;2012:256024.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Aubart FC, Abbara S, Maisonobe T, Cottin V, Papo T, Haroche J, Mathian A, Pha M, Gilardin L, Hervier B, Soussan M, Morlat P, Nunes H, Benveniste O, Amoura Z, Valeyre D. Symptomatic muscular sarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e443.CrossRefGoogle Scholar
  40. 40.
    Stern BJ, Royal W III, Gelfand JM, Clifford DB, Tavee J, Pawate S, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–53.PubMedCrossRefGoogle Scholar
  41. 41.
    Dale JC, O’Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74(5):535.PubMedCrossRefGoogle Scholar
  42. 42.
    Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191–7.PubMedGoogle Scholar
  43. 43.
    Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol. 2015;285:1–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Bathla G, Singh AK, Policeni B, Agarwal A, Case B. Imaging of neurosarcoidosis: common, uncommon, and rare. Clin Radiol. 2016;71(1):96–106.PubMedCrossRefGoogle Scholar
  46. 46.
    Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52(9):875–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Bitoun S, Bouvry D, Borie R, Mahevas M, Sacre K, Haroche J, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016;87(24):2517–21.PubMedCrossRefGoogle Scholar
  50. 50.
    Bradshaw MJ, Gelfand JM, Stern B, Clifford DB, Wang Y, Cho TA, Vu N, Sriram S, Moses H, Bagnato F, Koth LL, Hauser SL, Dierkhising J, Kaufmann JA, Ammah D, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of neurosarcoidosis: a multi-institutional case series. Neurology. 2017;88(16):Supplement P1.335.Google Scholar
  51. 51.
    Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis. 2017;11(3):378–83.PubMedGoogle Scholar
  52. 52.
    Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.PubMedCrossRefGoogle Scholar
  53. 53.
    AbdelRazek MA, Venna N, Stone JH. IgG4-related disease of the central and peripheral nervous systems. Lancet Neurol. 2018;17(2):183–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Lu LX, Della-Torre E, Stone JH, Clark SW. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. JAMA Neurol. 2014;71(6):785–93.PubMedCrossRefGoogle Scholar
  55. 55.
    Wu A, Andrew NH, McNab AA, Selva D. IgG4-related ophthalmic disease: pooling of published cases and literature review. Curr Allergy Asthma Rep. 2015;15(6):27.PubMedCrossRefGoogle Scholar
  56. 56.
    Soussan JB, Deschamps R, Sadik JC, Savatovsky J, Deschamps L, Puttermann M, et al. Infraorbital nerve involvement on magnetic resonance imaging in European patients with IgG4-related ophthalmic disease: a specific sign. Eur Radiol. 2017;27(4):1335–43.PubMedCrossRefGoogle Scholar
  57. 57.
    Ohyama K, Koike H, Takahashi M, Kawagashira Y, Iijima M, Watanabe H, et al. Immunoglobulin G4-related pathologic features in inflammatory neuropathies. Neurology. 2015;85(16):1400–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Stone JH, Brito-Zeron P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 2015;90(7):927–39.PubMedCrossRefGoogle Scholar
  59. 59.
    Hao M, Liu M, Fan G, Yang X, Li J. Diagnostic value of serum IgG4 for IgG4-related disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(21):e3785.CrossRefGoogle Scholar
  60. 60.
    Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014;134(3):679–87.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.PubMedCrossRefGoogle Scholar
  63. 63.
    Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Feigenbaum A. Description of Behcet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40(6):355–7.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Behçet H. Uber rezidivierende apthose durch ein virus verursachte gesuchwure am mund, am auge und an den genitalien. Dermatol Wochenschr. 1937;105:1152–7.Google Scholar
  67. 67.
    Gul A. Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4(1):81–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Zhang M, Xu WD, Wen PF, Liang Y, Liu J, Pan HF, et al. Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet’s disease: an updated meta-analysis. Mol Vis. 2013;19:1913–24.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Siva A, Saip S. The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513–29.PubMedCrossRefGoogle Scholar
  70. 70.
    Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Ann Rheum Dis. 1984;43(6):783–9.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Yazici H, Fresko I, Yurdakul S. Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3(3):148–55.PubMedCrossRefGoogle Scholar
  72. 72.
    Miller JJ, Venna N, Siva A. Neuro-Behcet disease and autoinflammatory disorders. Semin Neurol. 2014;34(4):437–43.PubMedCrossRefGoogle Scholar
  73. 73.
    Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.CrossRefGoogle Scholar
  74. 74.
    Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, et al. Behcet’s disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S58–64.PubMedGoogle Scholar
  75. 75.
    Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Bletry O, et al. Cerebral venous thrombosis in Behcet’s disease: clinical study and long-term follow-up of 25 cases. Neurology. 1992;42(3 Pt 1):614–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Bradshaw MJ, Pawate S, Bloch KC, Moots P, Reddy NM. Clinical reasoning: a 52-year-old man with diplopia and ataxia. Neurology. 2016;87(13):e140–3.PubMedCrossRefGoogle Scholar
  77. 77.
    Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis/brainstem encephalitis. Curr Neurol Neurosci Rep. 2011;11(6):543–52.PubMedCrossRefGoogle Scholar
  78. 78.
    International Team for the Revision of the International Criteria for Behcet’s Disease. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.CrossRefGoogle Scholar
  79. 79.
    Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of Neuro-Behcet’s disease: international consensus recommendations. J Neurol. 2014;261(9):1662–76.PubMedCrossRefGoogle Scholar
  80. 80.
    de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.PubMedCrossRefGoogle Scholar
  81. 81.
    Saruhan-Direskeneli G, Yentur SP, Mutlu M, Shugaiv E, Yesilot N, Kurtuncu M, et al. Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behcet’s disease. Clin Exp Rheumatol. 2013;31(3 Suppl 77):25–7.PubMedGoogle Scholar
  82. 82.
    Scully SE, Stebner FC, Yoest SM. Magnetic resonance spectroscopic findings in neuro-Behcet disease. Neurologist. 2004;10(6):323–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Borhani Haghighi A, Sarhadi S, Farahangiz S. MRI findings of neuro-Behcet’s disease. Clin Rheumatol. 2011;30(6):765–70.PubMedCrossRefGoogle Scholar
  84. 84.
    Albayram S, Saip S, Hasiloglu ZI, Teke M, Ceyhan E, Tutuncu M, et al. Evaluation of parenchymal neuro-Behcet disease by using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2011;32(6):1050–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Kao CH, Lan JL, ChangLai SP, Chieng PU. Technetium-99m-HMPAO SPECT and MRI of brain in patients with neuro-Behcet’s syndrome. J Nucl Med. 1998;39(10):1707–10.PubMedGoogle Scholar
  86. 86.
    Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008;267:41–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet’s syndrome. J Neurol Sci. 2008;272(1–2):99–105.PubMedCrossRefGoogle Scholar
  88. 88.
    Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S. Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol. 2011;30(7):1007–12.PubMedCrossRefGoogle Scholar
  89. 89.
    Sjögren H. Zur kenntnis der keratoconjunctivitis sicca (keratitis filiformis bei hypofunktion der tränendrüsen). Acta Ophthalmol. 1933;11(Suppl 2):1–151.Google Scholar
  90. 90.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Chai J, Logigian EL. Neurological manifestations of primary Sjogren’s syndrome. Curr Opin Neurol. 2010;23(5):509–13.PubMedCrossRefGoogle Scholar
  92. 92.
    Gono T, Kawaguchi Y, Katsumata Y, Takagi K, Tochimoto A, Baba S, et al. Clinical manifestations of neurological involvement in primary Sjogren’s syndrome. Clin Rheumatol. 2011;30(4):485–90.PubMedCrossRefGoogle Scholar
  93. 93.
    Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83(5):280–91.CrossRefGoogle Scholar
  94. 94.
    Berkowitz AL, Samuels MA. The neurology of Sjogren’s syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol. 2014;14(1):14–22.PubMedCrossRefGoogle Scholar
  95. 95.
    Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518–34.PubMedCrossRefGoogle Scholar
  96. 96.
    Margaretten M. Neurologic manifestations of primary Sjogren syndrome. Rheum Dis Clin N Am. 2017;43(4):519–29.CrossRefGoogle Scholar
  97. 97.
    Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468–76.PubMedGoogle Scholar
  98. 98.
    Bradshaw MJ, Kimbrough D. Neuromyelitis optica spectrum disorders. Pract Neurol. 2/2019. p. 76–89.Google Scholar
  99. 99.
    Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015;14(1):75–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A. 2006;103(52):19854–9.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28(1):61–73.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47(4):337–69.CrossRefGoogle Scholar
  105. 105.
    Ellison D, Gatter K, Heryet A, Esiri M. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol. 1993;46(1):37–40.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Timlin H, Petri M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus. 2013;22(12):1251–8.PubMedCrossRefGoogle Scholar
  107. 107.
    Jafri K, Patterson SL, Lanata C. Central nervous system manifestations of systemic lupus erythematosus. Rheum Dis Clin N Am. 2017;43(4):531–45.CrossRefGoogle Scholar
  108. 108.
    Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005;64(12):2102–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Piga M, Chessa E, Peltz MT, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16(3):244–52.PubMedCrossRefGoogle Scholar
  110. 110.
    Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry. 2006;77(3):290–5.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378–87.PubMedCrossRefGoogle Scholar
  112. 112.
    Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e231.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, Loza-Santamaria E, Rahman A, Munoz-Fernandez S, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013;65(11):1775–85.CrossRefGoogle Scholar
  114. 114.
    Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620–5.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–5.PubMedCrossRefGoogle Scholar
  117. 117.
    Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.CrossRefGoogle Scholar
  118. 118.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.CrossRefGoogle Scholar
  119. 119.
    Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, Sjogren syndrome, and rheumatoid arthritis. Semin Neurol. 2014;34(4):425–36.PubMedCrossRefGoogle Scholar
  120. 120.
    Dimberg EL. Rheumatology and neurology. Continuum (Minneap Minn). 2017;23(3, Neurology of Systemic Disease):691–721.Google Scholar
  121. 121.
    Agarwal V, Singh R, Wiclaf, Chauhan S, Tahlan A, Ahuja CK, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27(7):841–4.PubMedCrossRefGoogle Scholar
  122. 122.
    Yuh WT, Drew JM, Rizzo M, Ryals TJ, Sato Y, Bell WE. Evaluation of pachymeningitis by contrast-enhanced MR imaging in a patient with rheumatoid disease. AJNR Am J Neuroradiol. 1990;11(6):1247–8.PubMedGoogle Scholar
  123. 123.
    Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1989;18(4):258–66.PubMedCrossRefGoogle Scholar
  124. 124.
    Ramos M, Mandybur TI. Cerebral vasculitis in rheumatoid arthritis. Arch Neurol. 1975;32(4):271–5.PubMedCrossRefGoogle Scholar
  125. 125.
    Bradshaw MJ, Cho TA, Chow FC. Central nervous system infections associated with immunosuppressive therapy for rheumatic disease. Rheum Dis Clin N Am. 2017;43(4):607–19.CrossRefGoogle Scholar
  126. 126.
    DeQuattro K, Imboden JB. Neurologic manifestations of rheumatoid arthritis. Rheum Dis Clin N Am. 2017;43(4):561–71.CrossRefGoogle Scholar
  127. 127.
    Ozkul A, Yilmaz A, Akyol A, Kiylioglu N. Cerebral vasculitis as a major manifestation of rheumatoid arthritis. Acta Clin Belg. 2015;70(5):359–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Michael J. Bradshaw
    • 1
  • Shamik Bhattacharyya
    • 2
  • Nagagopal Venna
    • 3
    • 4
  • Jonathan F. Cahill
    • 5
  1. 1.Department of Neurology, Chicago Medical SchoolRosalind Franklin University of Medicine and Science, Billings ClinicBillingsUSA
  2. 2.Department of NeurologyBrigham and Women’s HospitalBostonUSA
  3. 3.Neuro-Infectious DiseasesHarvard Medical SchoolBostonUSA
  4. 4.Division of Neuroimmunology, Department of NeurologyMassachusetts General HospitalBostonUSA
  5. 5.Rhode Island Hospital and Alpert Medical School of Brown UniversityBrown NeurologyProvidenceUSA

Personalised recommendations